DE60041159D1 - VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind. - Google Patents

VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind.

Info

Publication number
DE60041159D1
DE60041159D1 DE60041159T DE60041159T DE60041159D1 DE 60041159 D1 DE60041159 D1 DE 60041159D1 DE 60041159 T DE60041159 T DE 60041159T DE 60041159 T DE60041159 T DE 60041159T DE 60041159 D1 DE60041159 D1 DE 60041159D1
Authority
DE
Germany
Prior art keywords
treatment
vegf receptor
vascular permeability
diseases characterized
ocular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041159T
Other languages
English (en)
Inventor
Nicholas J Papadopoulos
Stanley J Wiegand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60041159(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60041159D1 publication Critical patent/DE60041159D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
DE60041159T 1999-06-08 2000-05-23 VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind. Expired - Lifetime DE60041159D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
DE60041159D1 true DE60041159D1 (de) 2009-01-29

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60041159T Expired - Lifetime DE60041159D1 (de) 1999-06-08 2000-05-23 VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind.
DE60019415T Expired - Lifetime DE60019415T2 (de) 1999-06-08 2000-05-23 Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60019415T Expired - Lifetime DE60019415T2 (de) 1999-06-08 2000-05-23 Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften

Country Status (33)

Country Link
EP (2) EP1544299B1 (de)
JP (2) JP4723140B2 (de)
KR (1) KR100659477B1 (de)
CN (3) CN101433715B (de)
AT (2) ATE417928T1 (de)
AU (2) AU779303B2 (de)
BE (1) BE2013C029I2 (de)
BR (2) BRPI0011407B8 (de)
CA (1) CA2376379C (de)
CY (2) CY1108883T1 (de)
CZ (2) CZ302689B6 (de)
DE (2) DE60041159D1 (de)
DK (2) DK1544299T3 (de)
ES (2) ES2237429T3 (de)
FR (1) FR13C0028I2 (de)
HK (3) HK1043388A1 (de)
HR (1) HRP20010908B1 (de)
HU (3) HU229156B1 (de)
IL (3) IL146890A0 (de)
LT (1) LTC1183353I2 (de)
LU (1) LU92195I2 (de)
ME (2) MEP3208A (de)
MX (1) MXPA01012630A (de)
NO (3) NO330775B1 (de)
NZ (1) NZ515913A (de)
PL (1) PL208247B1 (de)
PT (2) PT1183353E (de)
RS (1) RS50073B (de)
RU (1) RU2265661C2 (de)
SK (1) SK287332B6 (de)
UA (1) UA74146C2 (de)
WO (1) WO2000075319A1 (de)
ZA (1) ZA200110068B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
WO2002060950A2 (en) 1994-11-14 2002-08-08 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US8183350B2 (en) 2002-05-04 2012-05-22 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
SI1608685T1 (sl) * 2003-03-28 2007-08-31 Regeneron Pharma Antagonisti VEGF za zdravljenje diabetesa
EP1646353A4 (de) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc Fusionsproteine zur behandlung des zns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
ES2636653T3 (es) 2003-05-16 2017-10-06 Acorda Therapeutics, Inc. Mutantes degradantes del proteoglucano para el tratamiento del SNC
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1631317A2 (de) * 2003-06-06 2006-03-08 Regeneron Pharmaceuticals, Inc. Verwendung von vegf-hemmern für tumorregression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
WO2005016369A1 (en) * 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist in combination with radiation therapy
WO2005112986A2 (en) 2004-05-18 2005-12-01 Acorda Therapeutics, Inc. Purifying chondroitinase and stable formulations thereof
EP1767546B1 (de) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
JP2008502738A (ja) 2004-06-10 2008-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
EP1755645A2 (de) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf-hemmer zur behandlung von maligner pleuraler effusion
EP1771189A2 (de) 2004-07-30 2007-04-11 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung von typ-1-diabetes mittels blockierung der vegf-vermittelten aktivität
DE602005021811D1 (de) 2004-09-13 2010-07-22 Genzyme Corp Multimere konstrukte
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
WO2007038548A2 (en) 2005-09-26 2007-04-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
AU2006326417B2 (en) † 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
EP2358746B1 (de) 2008-11-03 2020-09-16 Molecular Partners AG Bindungsproteine zum hemmen der vegf-a-rezeptorinteraktion
CN101838329A (zh) 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
EP3539991A1 (de) * 2011-01-07 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur verbesserung der physikalischen eigenschaften von antikörpern
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
US9988611B2 (en) 2011-12-01 2018-06-05 Ap Biosciences, Inc. Protein inhibitors to complement and VEGF pathways and methods of use thereof
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
AU2014218318B2 (en) 2013-02-18 2018-02-15 Vegenics Pty Limited Ligand binding molecules and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
DK3065761T3 (da) 2013-11-05 2020-02-17 Allergan Inc Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
EP3828202A1 (de) 2014-05-12 2021-06-02 Formycon AG Vorgefüllte spritze aus kunststoff mit einem vegf-antagonisten
PL3170005T3 (pl) 2014-07-18 2019-10-31 Sanofi Sa Sposób przewidywania wyniku leczenia afliberceptem u pacjenta podejrzewanego o chorobę nowotworową
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
SI3230316T1 (sl) 2014-12-11 2022-05-31 Bayer Healthcare Llc Zdravljenje starostne degeneracije makule z majhno aktivno horoidalno neovaskularizacijsko lezijo
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
JP6882738B2 (ja) 2015-11-18 2021-06-02 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ
AU2016356717B2 (en) 2015-11-18 2022-09-29 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
EP3377101A4 (de) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. Verfahren und zusammensetzungen zur vegf-bindung
IL302424A (en) 2015-12-03 2023-06-01 Regeneron Pharma Methods for associating genetic variants with clinical outcome in patients suffering from age-related macular degeneration and receiving treatment against tubular endothelial growth factor
EP3407868A1 (de) 2016-01-26 2018-12-05 Formycon AG Flüssigformulierung eines vegf-antagonisten
JPWO2018070390A1 (ja) 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
ES2887046T3 (es) 2017-08-17 2021-12-21 Just Evotec Biologics Inc Método de purificación de proteína glicosilada a partir de galectinas de las células hospedadoras y otros contaminantes
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
PE20210915A1 (es) * 2017-11-27 2021-05-19 4D Molecular Therapeutics Inc Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis
EP3716992B1 (de) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Verwendung eines vegf-antagonisten zur behandlung angiogener augenerkrankungen
IL275125B2 (en) 2017-12-13 2023-12-01 Regeneron Pharma Apparatus and methods for support management of chromatography column substrate and related methods
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
WO2020229584A1 (en) 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
MX2022002355A (es) 2019-09-03 2022-04-06 Amgen Inc Dispositivo de inyeccion para suministro de farmacos y envase para el dispositivo de inyeccion.
AU2020348947A1 (en) 2019-09-16 2022-03-10 Amgen Inc. Method for external sterilization of drug delivery device
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization
IL293286A (en) 2019-12-06 2022-07-01 Regeneron Pharma vegf mini-traps and methods of using them
MY190626A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
AU2021226754A1 (en) 2020-02-24 2022-07-07 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
EP4145456A1 (de) 2021-09-06 2023-03-08 Bayer AG Vorhersage einer änderung in zusammenhang mit einer makulaflüssigkeit
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
NO20016036D0 (no) 2001-12-10
AU5040400A (en) 2000-12-28
CA2376379A1 (en) 2000-12-14
JP5273746B2 (ja) 2013-08-28
CZ303656B6 (cs) 2013-01-30
RU2265661C2 (ru) 2005-12-10
NO2013010I1 (no) 2013-06-17
ZA200110068B (en) 2002-12-06
CA2376379C (en) 2007-08-07
DK1183353T3 (da) 2005-08-08
MEP3208A (xx) 2010-02-10
JP2003501089A (ja) 2003-01-14
HUP0201515A3 (en) 2004-12-28
KR100659477B1 (ko) 2006-12-20
BRPI0011407B8 (pt) 2021-05-25
AU779303B2 (en) 2005-01-13
CY2013019I2 (el) 2015-11-04
LTC1183353I2 (lt) 2023-02-27
DE60019415T2 (de) 2006-03-09
JP2011024595A (ja) 2011-02-10
BR0011407A (pt) 2002-04-02
NO332559B1 (no) 2012-10-29
YU86901A (sh) 2004-05-12
PT1183353E (pt) 2005-06-30
ATE417928T1 (de) 2009-01-15
NO20016036L (no) 2002-02-08
NO330775B1 (no) 2011-07-11
CY1108883T1 (el) 2014-07-02
AU2005201365A1 (en) 2005-04-28
HU230159B1 (hu) 2015-09-28
PT1544299E (pt) 2009-03-18
KR20020019070A (ko) 2002-03-09
NO20100656L (no) 2002-02-08
NO2013010I2 (no) 2013-05-15
UA74146C2 (uk) 2005-11-15
MXPA01012630A (es) 2002-07-22
CN101433715A (zh) 2009-05-20
HUP0201515A2 (en) 2002-08-28
LTPA2013009I1 (lt) 2013-06-25
IL146890A (en) 2008-07-08
DK1544299T3 (da) 2009-03-23
ATE293164T1 (de) 2005-04-15
FR13C0028I2 (fr) 2014-05-16
EP1544299B1 (de) 2008-12-17
SK287332B6 (sk) 2010-07-07
HK1185798A1 (en) 2014-02-28
EP1183353B1 (de) 2005-04-13
CN100523187C (zh) 2009-08-05
BE2013C029I2 (de) 2019-03-06
CZ302689B6 (cs) 2011-09-07
NZ515913A (en) 2004-01-30
BRPI0011407B1 (pt) 2018-09-25
HK1132653A1 (en) 2010-03-05
HUS1300052I1 (hu) 2016-08-29
CN103349781B (zh) 2015-04-01
IL146890A0 (en) 2002-08-14
CN101433715B (zh) 2013-04-17
RS50073B (sr) 2009-01-22
PL352246A1 (en) 2003-08-11
AU2005201365B2 (en) 2007-08-09
EP1544299A1 (de) 2005-06-22
FR13C0028I1 (fr) 2013-06-14
DE60019415D1 (de) 2005-05-19
ES2319305T3 (es) 2009-05-06
CN1369009A (zh) 2002-09-11
HRP20010908A2 (en) 2005-04-30
SK17522001A3 (sk) 2003-04-01
HK1043388A1 (en) 2002-09-13
WO2000075319A1 (en) 2000-12-14
ME00024B (me) 2010-02-10
JP4723140B2 (ja) 2011-07-13
EP1183353A1 (de) 2002-03-06
HRP20010908B1 (en) 2006-05-31
LU92195I2 (fr) 2013-07-15
HU229156B1 (en) 2013-09-30
IL190234A0 (en) 2008-11-03
PL208247B1 (pl) 2011-04-29
ES2237429T3 (es) 2005-08-01
CN103349781A (zh) 2013-10-16
CY2013019I1 (el) 2015-11-04
CZ20014387A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
DE60041159D1 (de) VEGF-Rezeptorchimären zur behandlung von Augenkrankheiten, welche durch vaskuläre Permeabilität charakterisiert sind.
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
DE69635565D1 (de) Antagonisten des vaskulären Endothelzellen-Wachstumfaktors
MX2010006422A (es) Proteinas de union a antigenos.
ATE404199T1 (de) Verwendung von naloxon zur behandlung von essstörungen
ATE194081T1 (de) Verfahren zur behandlung von verletzungen retinaler ganglione mit neurotrophischem faktor aus der glialzellinie (gdnf)
WO2007112675A8 (fr) Protéine de fusion du récepteur du vegf et son utilisation
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DK1284959T3 (da) Forbindelser til modulering af RAGE-receptoren
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
FR2816633B1 (fr) Methode de criblage d'agents susceptibles de traiter l'obesite
TH55765B (th) โปรตีนที่มีความว่องไวในการเป็นตัวปรับบังคับในการสร้างเส้นเลือดใหม่
UA43242A (uk) Спосіб лікування офтальмологічних патологій

Legal Events

Date Code Title Description
8364 No opposition during term of opposition